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Background: Staphylococcus aureus 
bacteraemia (SAB) causes high morbidity, 
mortality and healthcare costs. There are 
national recommendations for minimal 14 
days of IV antibiotics, repeat blood cultures 
and screen for endocarditis. Study was 
conducted in University Hospital Coventry 
(UHC). It is a most modern healthcare facility 
in Europe with 1,005 beds, 26 operating 
theatres and specialize in cardiology, 
neurosurgery, stroke, joint replacements, in 
vitro fertilization and maternal health, 
diabetes and kidney transplants. 
Management of SAB is continuously audited 
in UHC since 2007. The standard treatment 
pathway for the trust is underway.  
 
Objectives: This is to assess the standard of 
care in management of SAB comparing the 
results of past 3-years and looking forward 
for further development.  
 
Methods: Retrospective study conducted 
between June 2016 to December 2018. 
Electronic patient records were used.  
 
Results: Total 153 patients were identified 
with SAB. Majority were >60 years. There 
were 25 intravenous drug users in the group 
and 6 presented with recurrence. There were 
only 2% MRSAs. In majority (28%), the source 
of infection was skin and soft tissue 
infections. Surveillance blood cultures were 
done in 76% patients. It is improved form 67% 
in last audit which was conducted between 
June 2016 and May2018. Fifty one percent 
had undergone echocardiogram and 8% 
patients died before blood culture results are 
available. In 89% of patients appropriate 
treatment was started. More than 14 days of 
treatment was completed in 81% patients. 
Flucloxacillin, meropenem, ertapenem, 
daptomycin and other antibiotics were used 
for the completion of 14 days course. From 
total patients, 16% had complications and 
endocarditis was the commonest. The 60 
days mortality rate was 21%.  
 
Conclusions: The mortality rate and 
complications of SAB is high disregard of the 
effective antibiotics and further 
improvement of the clinical management is 
essential. 
 
  
